Key facts
- Avenzo Therapeutics’s last known valuation is $590.0M (Aug 2025).
- It has raised $445.9M across 2 recorded rounds; the latest was Early Stage VC ($47.2M) in Aug 2025.
- Notable investors include New Enterprise Associates, OrbiMed, Sands Capital, Foresite Capital, INCE Capital — 15 tracked in total.
- Avenzo Therapeutics has filed 4 Form Ds with the SEC since 2022, most recently Sep 2025 ($47.2M sold to 20 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Avenzo Therapeutics
Funding rounds
2 roundsAbout Avenzo Therapeutics
Operator of a clinical-stage oncology platform intended to develop novel treatments for underserved cancers. The company's platform offers a pipeline of oncology drug candidates, focusing on rare and genomically defined cancers, enabling researchers and patients to advance treatment through targeted therapies.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2022
- Employees
- 45
- Website
- avenzotx.com/
- Ownership
- Privately Held (backing)
Avenzo Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Avenzo Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Avenzo Therapeutics in its N-PORT filings yet. We sweep new filings monthly.